Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enzyme inhibitor, enalapril, in children and adults with C3 glomerulopathy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515892-36-00

Enrollment

Registered

2024-07-10

Start date

2020-01-01

Completion date

Unknown

Last updated

2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C3 glomerulopathy

Brief summary

Serum C3 during the cross-over study., Serum C3 and complement deposition in renal biopsies during the extension study.

Detailed description

Complement activation (such as serum C3a, C3d, C5a and other complement assays), Proteinuria, Kidney function, Kidney biopsy findings, Blood pressure, Activation of the renin-angiotensin system

Interventions

DRUGEnalapril Viatris 5 mg comprimidos EFG

DRUGRasilez 300 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Serum C3 during the cross-over study., Serum C3 and complement deposition in renal biopsies during the extension study.	—

Secondary

Measure	Time frame
Complement activation (such as serum C3a, C3d, C5a and other complement assays), Proteinuria, Kidney function, Kidney biopsy findings, Blood pressure, Activation of the renin-angiotensin system	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026